Strides Arcolab, a Bangalore-based pharmaceutical company with a focus on development and manufacture of IP-led niche generics and bio-pharmaceuticals, on Friday announced that it has received approval from the United States Food & Drug Administration (US FDA) for Methoxsalen Capsules USP, 10 mg (Soft Gelatin Capsules).
Methoxsalen is a drug used to treat psoriasis, eczema, vitiligo and some cutaneous lymphomas in conjunction with exposing the skin to UVA light from lamps or sunlight. Methoxsalen modifies the way skin cells receive the UVA radiation, clearing up the disease.
According to IMS data, the US market for generic Methoxsalen Capsule is approximately $13.6 million with no generic player.
The product will be manufactured at the company’s US FDA-approved oral dosage facility in Bangalore and marketed directly by Strides in the US Market.
Strides Arcolab shares gained 9.54 per cent to close at Rs 599 on the BSE in a strong Mumbai market on Friday.
(Edited by Joby Puthuparampil Johnson)
Leave Your Comment
4 years ago
Strides Arcolab Limited has entered into a licensing agreement with Gilead...
3 years ago
Strides Arcolab Ltd, a Bangalore-based pharmaceutical company, has received its...
5 years ago
Bangalore-based Strides Arcolab Ltd has received a nod from US Food and Drug...